<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634995</url>
  </required_header>
  <id_info>
    <org_study_id>IM026-002</org_study_id>
    <secondary_id>2017-003729-13</secondary_id>
    <nct_id>NCT03634995</nct_id>
  </id_info>
  <brief_title>An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of BMS-986256, and a Relative Bioavailability Study in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of the experimental medication
      BMS-986256 in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG, vital signs, physical examination findings, or clinical laboratory assessments</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) leading to early discontinuation</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (kel)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T-half)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio for AUC(INF) [MR(AUC[INF])]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio of Cmax [MR(Cmax)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration immediately prior to dosing (Ctrough)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of Ctrough [AR(Ctrough)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of AUC(TAU) [AR(AUC[TAU])]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of Cmax [AR(Cmax)]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio for AUC(TAU) [MR(AUC[TAU])]</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single doses of BMS-986256</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending multiple doses of BMS-986256</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential multiple doses of BMS-986256</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986256</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_label>Sequential Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_label>Sequential Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Weight ≥ 50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive at
             screening

          -  Participants must not be current users (within 6 months before screening) of tobacco
             or tobacco- or nicotine-containing products; they must also be willing to refrain from
             using any of these products during their participation in the study

          -  A negative QuantiFERON®-TB Gold test result at screening or documentation of a
             negative result within 3 months before screening

        Exclusion Criteria:

          -  Previous participation in the current study or previous exposure within 6 weeks before
             study drug administration for non-biologics and 12 weeks before study drug
             administration for biologics

          -  Inability to tolerate oral medication

          -  Inability to tolerate venipuncture, or inadequate venous access

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Science KK</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

